GSK Reports Q3 2026 Sales of £8.9 Billion, Up 5%

GSK announced its third-quarter 2026 financial results, reporting total sales of £8.9 billion, a 5% increase at constant exchange rates. Core earnings per share (EPS) reached 54.6 pence, surpassing the analyst consensus of 50.4 pence. Growth was primarily driven by the Specialty Medicines segment, which saw a 15% increase in sales, including a 10% rise in HIV products and a 23% increase in oncology. The company reaffirmed its full-year 2026 guidance, projecting turnover growth in the upper half of 3% to 5% and core EPS growth in the lower half of 7% to 9% at constant exchange rates. Additionally, GSK highlighted progress in its R&D pipeline, including regulatory approvals for new treatments and the initiation of multiple Phase III trials, while noting a £328 million charge related to its ongoing savings program.